Q4 FY2025 · ended Dec 31, 2025 · Revenue $-251,000 · Filed Mar 10, 2026
Artiva Biotherapeutics, Inc. (ARTV) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$20.8 million. As of Jun 30, 2026 it held $349.4 million in cash and investments and $9.8 million in total debt.
Revenue
$-251,000
Net income
$-25.00M
-17.6% vs year-ago quarter
Operating cash flow
$-20.36M
+11.4% vs year-ago quarter
Free cash flow
$-20.77M
+13.6% vs year-ago quarter
EPS
$-0.63
+27.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
48.89M
+100.2% vs year-ago quarter
Net cash
$339.55M
Q2 FY2026
Operating margin
8737.8%
Q4 FY2025
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ARTV (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1817241
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | -$251,000 | — | — |
| Operating income | -$26.9M | -$24.4M | -$21.9M | -$22.9M | -$22.8M |
| Net income | -$25.0M | -$23.5M | -$20.8M | -$21.5M | -$21.3M |
| Diluted EPS | -$0.63 | -$0.95 | -$0.85 | -$0.88 | -$0.87 |
| Operating cash flow | -$20.4M | -$20.9M | -$14.7M | -$19.2M | -$23.0M |
| Free cash flow | -$20.8M | -$21.2M | -$15.1M | -$19.8M | -$24.0M |
| Total assets | $368.6M | $106.0M | $130.9M | $148.9M | $169.4M |
| Total liabilities | $21.1M | $18.1M | $21.0M | $19.6M | $20.4M |
| Stockholders' equity | $347.5M | $87.8M | $110.0M | $129.2M | $149.0M |
| Cash and investments | $349.4M | $86.8M | $108.0M | $123.0M | $142.4M |
| Total debt | $9.8M | $10.3M | $10.9M | $11.7M | $13.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Exit or restructuring costs
|
Oct 27, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Sep 11, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| ARS | Annual report to shareholders | Aug 3, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Other events
|
Jul 22, 2026 | Jul 22, 2026 |
All 232 Artiva Biotherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.